MET and Miyoshi myopathy: Accordingly, Zhang et al. [33] demonstrated that targeting C-MET via the SL1 aptamer [34,35] could be a potential therapeutic approach in MM, showing that SL1 was able to inhibit HGF-dependent C-MET signaling and suppress MM cell growth in vitro.